POD-09.03: Endovesical epirubicin and interferon α 2b is comparable to BCG as adjuvant treatment for T1 tumours with or without CIS

Autor:	Miloš Duchek, P.U. Malmström, O. Mestad, S. Hellsten, Staffan Jahnson, Fredrik Wiklund, Pekka Hellström
Rok vydání:	2007
Předmět:	Point of delivery business.industry Urology medicine.medical_treatment Cancer research Interferon α-2b Medicine business Adjuvant Epirubicin medicine.drug
Zdroj:	Urology. 70:28
ISSN:	0090-4295
DOI:	10.1016/j.urology.2007.06.109
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::eb8f98bf08a205106d57914d417a865e https://doi.org/10.1016/j.urology.2007.06.109 Zobrazit plný text záznamu Full Text from ScienceDirect